MMRi62 (7-[(2,3-dichlorophenyl)-(pyridin-2-ylamino)methyl]quinolin-8-ol), a ferroptosis inducer targeting MDM2-MDM4 (negative regulators of tumor suppressor p53). MMRi62 shows a P53-independent pro-apoptotic activity against pancreatic ductal adenocarcinoma (PDAC) cells and induce autophagy. MMRi62 inducesferroptosis, resulting in a increase of reactive oxygen and lysosomal degradation of ferritin heavy chain (FTH1). MMRi62 also leads to proteasomal degradation of mutant p53, also inhibits orthotopic xenograft PDAC mouse model in vivo with high frequency mutation characteristics of KRAS and TP53.12.

MMRi62 inhibits the proliferation, cloning and spherical growth of pancreatic ductal adenocarcinoma cells (PDAC) by inducing cell death [1]. MMRi62 (3 nM-100 μ M; 4 h) Combined with the ring heterodimer of MDM2 and MDM4, Kd value is 1.39 μ M. MMRi62 (10 nM-1 μ M; 72 h) to induce apoptosis of leukemia cells, and the IC50 to inhibit leukemia cells are 0.34 respectively μ M (HL60) and 0.22 μ M (HL60VR). MMRi62 (5 μ M, 10 μ M; 24 h) Reduce the autoubiquitination of MDM2B and increase the ubiquitination of MDM4 in a dose dependent manner. MMRi62 is an E3 ligase modifier that can switch substrate preference from MDM2 to MDM4. MMRi62 (5 μ M; 24, 72 h) induced apoptosis, independent of p53 [2].

MMRi62 showed anti-tumor activity in the orthotopic xenotransplantation PDAC mouse model by inhibiting the down-regulation of NCOA4 and mutant p53 to inhibit tumor growth in mice. MMRi62 also completely eliminates metastasis of tumors in situ [1].